Japan; Hiroshi Miyamoto, Rochester, NY INTRODUCTION AND OBJECTIVES: Recent preclinical evidence suggests the involvement of ER signaling in urothelial tumorigenesis, although its underlying mechanisms remain unclear. Meanwhile, cross-talk between FOXO1, a transcriptional factor known to induce apoptosis through the PI3K-Akt pathway, and ERb has been demonstrated in prostate cancer cells. We therefore investigated the role of FOXO1 in neoplastic transformation of urothelial cells in relation to ERb signaling.
INTRODUCTION AND OBJECTIVES: Recent preclinical evidence suggests the involvement of ER signaling in urothelial tumorigenesis, although its underlying mechanisms remain unclear. Meanwhile, cross-talk between FOXO1, a transcriptional factor known to induce apoptosis through the PI3K-Akt pathway, and ERb has been demonstrated in prostate cancer cells. We therefore investigated the role of FOXO1 in neoplastic transformation of urothelial cells in relation to ERb signaling.
METHODS: We immunohistochemically stained for ERb and phospho-FOXO1 (p-FOXO1), an inactive form of FOXO1, in the tissue microarrays consisting of 99 cases of upper urinary tract urothelial carcinoma and paired non-neoplastic urothelium. Then, in ERa(-)/ ERb(+) human normal urothelial SVHUC sublines stably expressing control-or FOXO1-shRNA with or without exposure to a chemical carcinogen 3-methylcholanthrene (MCA), we assessed the expression of FOXO1 and other known tumor suppressors (via RT-PCR and western blot) as well as neoplastic transformation (via MTT assay and mouse xenograft model).
RESULTS: ERb and p-FOXO1 were positive in 63% and 100% of urothelial tumors, which were significantly lower and higher than in non-neoplastic urothelial tissues [85% (P¼0.001) and 94% (P¼0.018)], respectively. In addition, there was a significant correlation between strong (3+) p-FOXO1 expression and ERb positivity (P¼0.002). In SVHUC cells, estradiol reduced FOXO1 expression, which was abolished by an anti-estrogen tamoxifen. FOXO1 knockdown considerably accelerated neoplastic transformation of MCA-SVHUC cells. Moreover, the expression levels of several genes known to inhibit urothelial carcinogenesis (e.g. p21, p27, UGT1A) were significantly lower in MCA-SVHUC-FOXO1-shRNA than in control cells. Notably, tamoxifen treatment resulted in inhibition of neoplastic transformation of control cells, which was abolished by a FOXO1 inhibitor AS1842856. However, no significant effects of tamoxifen on neoplastic transformation were seen in MCA-SVHUC-FOXO1-shRNA cells.
CONCLUSIONS: FOXO1 appeared to function as a tumor suppressor and could strongly prevent urothelial tumorigenesis. In contrast, ERb signals were found to promote it presumably via downregulation of FOXO1 expression. Accordingly, FOXO1 stimulation via an activator, together with ERb inactivation via an anti-estrogen, has the potential of being an effective chemopreventive approach for urothelial carcinoma. patients have been shown to be less likely to respond to BCG therapy, compared with female patients. Meanwhile, emerging preclinical evidence suggests the involvement of androgen receptor (AR) signaling in urothelial tumorigenesis and cancer progression. This study aims to assess whether AR signals have an impact on the direct cytotoxic effects of BCG on BC cell growth.
Source of
METHODS: We compared the inhibitory effects of BCG on BC cell viability, colony formation, or cell migration, between AR-positive (e.g. UMUC3, 5637/647V stably expressing wild-type AR) versus ARnegative lines (e.g. UMUC3 stably expressing AR-shRNA, 5637/647V) or between AR-positive lines with versus without treatment with a synthetic androgen methytrienolone (R1881) and/or an anti-androgen hydroxyflutamide (HF). We also determined the expression of AR and PTEN (whose knockdown in BC cells has correlated with increased BCG uptake) in these AR-positive/negative lines as well as in "BCGresistant" UMUC3/5637-AR/647V-AR sublines established following long-term culture with low-doses of BCG, using western blot. Immunohistochemistry (IHC) of AR was then performed in tissue microarrays consisting of BCs from patients who subsequently underwent BCG therapy.
RESULTS: BCG treatment reduced the numbers of viable cells or colonies of AR-negative lines more significantly than those of ARpositive lines. Similarly, in AR-positive cells cultured in an androgendepleted condition and in the presence of androgens, R1881 and HF treatments lowered and enhanced the BCG effects, respectively. In addition, BCG more significantly inhibited cell migration of AR-negative lines or AR-positive lines with mock treatment, compared to AR-positive lines without or with R1881 treatment, respectively. Furthermore, the expression levels of AR and PTEN were considerably elevated in R1881-treated AR-positive lines as well as BCG-resistant sublines, compared to respective controls. Finally, IHC showed AR positivity in 2 (14%) of 14 responders versus 8 (57%) of 14 non-responders (P¼0.046), and the difference was even more significant in male patients [2/13 (15%) vs. 7/11 (64%); P¼0.033].
CONCLUSIONS: These findings suggest that AR activity correlates with resistance to BCG treatment in BC cells. Accordingly, anti-androgenic drugs may function as sensitizers of BCG therapy especially in male patients with AR-positive BC.
Source of Funding: None

MP88-10 INHIBITION OF LIM AND SH3 DOMAIN PROTEIN 1 DELAYS CISPLATIN-RESISTANT BLADDER TUMOR PROGRESSION
Takashi Dejima*, Ario Takeuchi, Masaki Shiota, Masatoshi Eto, Fukuoka, Japan; Martin Gleave, Christopher Ong, Vancouver, Canada INTRODUCTION AND OBJECTIVES: Bladder cancer is the 6th most common cancer in the USA. The current standard therapy for the first line of metastatic or local advanced bladder cancer is combination therapy with cisplatin (CDDP) and gemcitabine (GEM). However 5years survival is still below 50%; therefore additional therapy is needed. LIM-SH3 domain protein 1 (LASP1), identified from cDNA library of metastatic axillary lymph nodes of breast cancer, has been shown to promote cancer progression and invasion in several malignancies. In bladder cancer, LASP1 expression associates with cell invasion and can be used for detecting bladder cancer. However, the anti-tumor effects of LASP1 knockdown in vivo as well as combination therapy with chemotherapy remain unclear. In this study, we investigated the anticancer activity of LASP1 knockdown in bladder cancer.
METHODS: LASP1 gene expression of tumor samples is analyzed using the Affymetrix Exon Array. The LASP1 expression in several bladder cancer cell lines was assessed by Western blot analysis and quantitative reverse transcription-PCR. Silencing of LASP1 in vitro was achieved using siRNA. Cell growth was measured by crystal violet assay. Cell cycle distribution was analyzed by flow cytometry after double thymidine block. The In vivo effect of LASP1 antisense oligonucleotide (ASO) treatment was assessed in the T24 CDDP-R (cisplatin-resistant) orthotopic bladder cancer model. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1177
